{"entity":{"id":"cipla","kind":"company","name":"Cipla","aka":[],"tldr":"The Mumbai generics maker famous for a one-dollar-a-day HIV regimen, which sells oncology generics across India and Africa and in 2026 partnered with ImmunoACT to take Indian CAR-T therapy to Africa.","summary":"Cipla was founded in Mumbai in 1935 by Khwaja Abdul Hamied and is India's third-largest drug producer. Its reputation rests on the early-2000s antiretroviral combination it sold for about 300 dollars a year against 12,000 dollars for the branded regimen, and it has applied the same approach to oncology generics and biosimilars for India and emerging markets. In 2026 ImmunoACT announced a collaboration with Cipla to distribute NexCAR19 in South Africa, Algeria and Morocco, the first export of an Indian CAR-T therapy.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Cipla","links":[{"label":"Official website","url":"https://www.cipla.com"}],"tags":[],"related":[],"cancers":[],"sections":["chemotherapy","cell-therapy"],"technologies":["car-t","cytotoxic-chemotherapy"],"targets":[],"drugs":["talicabtagene-autoleucel"],"companies":["immunoact"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-global-access","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Mumbai","country":"IN","companyType":"pharma","website":"https://www.cipla.com","ticker":"CIPLA.NS","founded":1935,"investors":[],"funding":[]},"route":"/companies/cipla/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"oral-solid-dose-manufacturing","kind":"technology","name":"Oral solid dose manufacturing (tablets and capsules)","route":"/technologies/oral-solid-dose-manufacturing/"},{"id":"small-molecule-api-synthesis","kind":"technology","name":"Small-molecule API synthesis","route":"/technologies/small-molecule-api-synthesis/"}],"drug":[{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/"}],"company":[{"id":"immunoact","kind":"company","name":"ImmunoACT","route":"/companies/immunoact/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"term":[{"id":"nexavar-compulsory-licence","kind":"term","name":"Nexavar compulsory licence (India, 2012)","route":"/terms/nexavar-compulsory-licence/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}